넥타르 테라퓨틱스(NKTR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $67.10 (-1.84%), 시가총액 $1.98B, 52주 최저~최고 $0.49 ~ $73.86.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (T
넥타르 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
넥타르 테라퓨틱스의 현재 주가는 $67.10 (-1.84%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
넥타르 테라퓨틱스의 시가총액은 약 $1.98B입니다.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and int